摘要
沿着血管生成途径的配体和受体之间的相互作用的特异性阻断代表了增强功效以及减少化学疗法不良反应的有效方法。 在过去十年中,这种治疗策略在癌症治疗中的应用进展很快。 抗血管生成治疗是卵巢癌最有希望的靶向治疗。 在一线设置或疾病复发中,将贝伐珠单抗添加到常规化学疗法中,可以改善卵巢癌患者的总体存活(OS),至少在预后不良的一部分患者中。 在本文中,我们总结了卵巢癌中用于抗血管生成治疗的主要药物的公布数据。 我们将回顾现有药剂的分子机制,临床试验结果,并描述新药的发展。 还讨论了血管生成抑制剂的局限性和副作用。
关键词: 卵巢癌,分子靶向,抗血管生成剂,血管发生,癌症治疗,抑制剂。
Current Drug Targets
Title:Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Volume: 18 Issue: 10
关键词: 卵巢癌,分子靶向,抗血管生成剂,血管发生,癌症治疗,抑制剂。
摘要: Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Export Options
About this article
Cite this article as:
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170329095807
DOI https://dx.doi.org/10.2174/1389450118666170329095807 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer
Current Pharmaceutical Design Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles
Current Pharmaceutical Design Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Dendrimer-Based Contrast Agents for Molecular Imaging
Current Topics in Medicinal Chemistry Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release
Current Medicinal Chemistry Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Chemical Engineering Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Editorial: (Thematic Issue: Nanofluidics and Microfluidics: Novel Approaches in Biomedical Science)
Current Proteomics Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets